PL3615541T3 - Postaci polimorficzne i postaci stałe (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3- ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanoamidu i sposoby wytwarzania - Google Patents

Postaci polimorficzne i postaci stałe (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3- ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanoamidu i sposoby wytwarzania

Info

Publication number
PL3615541T3
PL3615541T3 PL18728514.3T PL18728514T PL3615541T3 PL 3615541 T3 PL3615541 T3 PL 3615541T3 PL 18728514 T PL18728514 T PL 18728514T PL 3615541 T3 PL3615541 T3 PL 3615541T3
Authority
PL
Poland
Prior art keywords
oxooxazolidin
oxazepin
dihydrobenzo
propanamide
polymorphs
Prior art date
Application number
PL18728514.3T
Other languages
English (en)
Inventor
Paroma CHAKRAVARTY
Chong Han
Sean M. Kelly
Karthik Nagapudi
Scott Savage
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3615541T3 publication Critical patent/PL3615541T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PL18728514.3T 2017-04-28 2018-04-26 Postaci polimorficzne i postaci stałe (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3- ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanoamidu i sposoby wytwarzania PL3615541T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491812P 2017-04-28 2017-04-28
PCT/EP2018/060820 WO2018197653A1 (en) 2017-04-28 2018-04-26 Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Publications (1)

Publication Number Publication Date
PL3615541T3 true PL3615541T3 (pl) 2025-06-23

Family

ID=62492573

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18728514.3T PL3615541T3 (pl) 2017-04-28 2018-04-26 Postaci polimorficzne i postaci stałe (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3- ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanoamidu i sposoby wytwarzania

Country Status (13)

Country Link
US (4) US20180339997A1 (pl)
EP (2) EP4534148A3 (pl)
JP (2) JP6998969B2 (pl)
KR (1) KR102342776B1 (pl)
CN (1) CN110650963B (pl)
AU (1) AU2018259089B2 (pl)
CA (1) CA3048591A1 (pl)
ES (1) ES3027566T3 (pl)
IL (3) IL298518B2 (pl)
MX (1) MX394540B (pl)
PL (1) PL3615541T3 (pl)
TW (1) TWI826373B (pl)
WO (1) WO2018197653A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
EP4534148A3 (en) 2017-04-28 2025-05-21 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
CN112313202A (zh) * 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
KR20220034129A (ko) * 2019-07-07 2022-03-17 올레마 파마슈티컬스 인코포레이티드 에스트로겐 수용체 길항제 요법
MX2022002415A (es) 2019-08-26 2022-03-22 Arvinas Operations Inc Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
AU2020389670A1 (en) * 2019-11-25 2022-05-19 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
TWI801730B (zh) * 2020-04-07 2023-05-11 神雲科技股份有限公司 具系統設定資料同步功能的伺服器
TW202440096A (zh) 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
PE20121025A1 (es) * 2009-09-28 2012-08-06 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la p13k
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
RU2018119749A (ru) 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
EP4534148A3 (en) 2017-04-28 2025-05-21 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production

Also Published As

Publication number Publication date
EP3615541C0 (en) 2025-03-19
WO2018197653A1 (en) 2018-11-01
MX394540B (es) 2025-03-21
EP4534148A3 (en) 2025-05-21
ES3027566T3 (en) 2025-06-16
US12410189B2 (en) 2025-09-09
IL267464B2 (en) 2023-05-01
US20200399286A1 (en) 2020-12-24
JP2020517713A (ja) 2020-06-18
US11591345B2 (en) 2023-02-28
IL298518A (en) 2023-01-01
IL267464A (en) 2019-08-29
CN110650963A (zh) 2020-01-03
TWI826373B (zh) 2023-12-21
EP3615541A1 (en) 2020-03-04
TW201843160A (zh) 2018-12-16
WO2018197653A9 (en) 2019-09-19
MX2019012507A (es) 2019-12-19
US20210094970A1 (en) 2021-04-01
IL267464B1 (en) 2023-01-01
EP3615541B1 (en) 2025-03-19
AU2018259089B2 (en) 2022-05-12
EP4534148A2 (en) 2025-04-09
JP6998969B2 (ja) 2022-02-10
US11028100B2 (en) 2021-06-08
US20230167128A1 (en) 2023-06-01
US20180339997A1 (en) 2018-11-29
IL317762A (en) 2025-02-01
KR20190133724A (ko) 2019-12-03
AU2018259089A9 (en) 2019-10-10
JP2021181446A (ja) 2021-11-25
BR112019013292A2 (pt) 2019-12-10
KR102342776B1 (ko) 2021-12-23
AU2018259089A1 (en) 2019-07-04
IL298518B1 (en) 2025-01-01
CA3048591A1 (en) 2018-11-01
CN110650963B (zh) 2022-09-27
IL298518B2 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
IL267464A (en) Polymorphs and solid forms of (s)-2-((2-((s-4-(difluoromethyl)-2-oxoxolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][ 1,4]oxazepin-9-yl)amino)propanamide and methods of production
IL281087A (en) Process for preparing (S)-2-((2-((S)-4-(difluoromethyl)-2-oxoxazolidine-3-YL)-6,5-dihydrobenzo[F]imidazo[2,1-D][4 , 1]oxazapine-9-YL)amino)propanamide
IL288080A (en) A process for the preparation of h7-pyrrolo[3,2-d]pyrimidine derivatives and their artificial intermediates
EP3231805A4 (en) Salt of pyrrolo[2,3-d]pyrimidine compound and novel polymorph of salt
PL3412672T3 (pl) Postać krystaliczna A 2-butoksy-7-(4-(pirolidyn-1-ylometylo)benzylo)-5H-pirolo[3,2- d]pirymidyno-4-aminy jako agonisty TLR7, sposób wytwarzania i jej zastosowanie
IL260999B (en) A method for the preparation of a pyrrolo[3,2-d] pyrimidine compound, and its intermediates
EP3728241A4 (en) OPICAPONE PREPARATION PROCESS AND INTERMEDIARIES THEREOF
PL3458615T3 (pl) Biotechnologiczny sposób wytwarzania akrylamidu i odpowiedni nowy szczep bakteryjny
SI3717476T1 (sl) Postopek priprave 2-(5-metoksiizokroman-1-il)-4,5-dihidro-1H-imidazola in njegove hidrogensulfatne soli
EP3717456A4 (en) PROCESS FOR PREPARING ROXADUSTAT AND ITS INTERMEDIARIES
IL248965A0 (en) Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d] [1,4]oxazapine-9-yl)-2-methylpropanamide, preparation methods and their pharmaceutical uses
PL3621941T3 (pl) Zastosowanie prekursorów do wytwarzania aminokwasów znakowanych węglem 11C oraz ich pochodnych
PL3524910T3 (pl) Grzejnik oraz sposób jego wytwarzania
GB201911627D0 (en) Polymorph of venetoclax and method for preparing the polymorph
TWI799450B (zh) 製備掌性α鹵烷酸之方法
HK40008399A (en) Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
HK40015980A (en) Polymorphs of sepiapterin and salts thereof